Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139


Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.

Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nitz UA, Hartmann A.

Int J Cancer. 2008 Sep 15;123(6):1433-8. doi: 10.1002/ijc.23628.


Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.

Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3.


Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.

Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.

Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.


High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.


Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.

Zhang Y, Zhang M, Yu F, Lu S, Sun H, Tang H, Peng Z.

J Exp Clin Cancer Res. 2015 Dec 1;34:145. doi: 10.1186/s13046-015-0261-3.


Nuclear karyopherin-α2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer.

Altan B, Yokobori T, Mochiki E, Ohno T, Ogata K, Ogawa A, Yanai M, Kobayashi T, Luvsandagva B, Asao T, Kuwano H.

Carcinogenesis. 2013 Oct;34(10):2314-21. doi: 10.1093/carcin/bgt214. Epub 2013 Jun 8.


Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.

Erben PB, Brunner K, Hecht M, Haderlein M, Büttner-Herold M, Agaimy A, Fietkau R, Hartmann A, Distel LV.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15814-24. eCollection 2015.


Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.

Schneeweiss A, Goerner R, Hensel MA, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G.

Biol Blood Marrow Transplant. 2001;7(6):332-42.


KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ.

Dankof A, Fritzsche FR, Dahl E, Pahl S, Wild P, Dietel M, Hartmann A, Kristiansen G.

Virchows Arch. 2007 Nov;451(5):877-81. Epub 2007 Sep 27.


Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.

Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ.

Clin Cancer Res. 2006 Jul 1;12(13):3950-60.


KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.

Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2015 Jun 9;112(12):1929-37. doi: 10.1038/bjc.2015.165. Epub 2015 May 19.


Significance of karyopherin-{alpha} 2 (KPNA2) expression in esophageal squamous cell carcinoma.

Sakai M, Sohda M, Miyazaki T, Suzuki S, Sano A, Tanaka N, Inose T, Nakajima M, Kato H, Kuwano H.

Anticancer Res. 2010 Mar;30(3):851-6.


KPNA2 over-expression is a potential marker of prognosis and therapeutic sensitivity in colorectal cancer patients.

Takada T, Tsutsumi S, Takahashi R, Ohsone K, Tatsuki H, Suto T, Kato T, Fujii T, Yokobori T, Kuwano H.

J Surg Oncol. 2016 Feb;113(2):213-7. doi: 10.1002/jso.24114. Epub 2015 Dec 10.


Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.

Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, Artinger V, Diallo-Danebrock R, Ting E, Mohrmann S, Poremba C, Harbeck N, Nitz U, Hartmann A, Gaumann A.

Breast Cancer Res Treat. 2011 Apr;126(3):643-51. doi: 10.1007/s10549-011-1377-6. Epub 2011 Feb 12.


Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G.

Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Erratum in: Clin Breast Cancer. 2012 Oct;12(5):386.


KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.

Gousias K, Niehusmann P, Gielen G, Simon M, Boström J.

J Clin Neurosci. 2014 Oct;21(10):1719-24. doi: 10.1016/j.jocn.2014.01.011. Epub 2014 Jun 11.


Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI.

Ann Surg. 2001 May;233(5):630-8.


Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.


Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.


Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.

Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Cancer. 2003 Apr 1;97(7):1591-600.

Supplemental Content

Support Center